

Table E1

Fanconi Anemia		Translesion Synthesis		Homologous Recombination		Mismatch Repair		Base Excision Repair		Non-Homologous End Joining		Chromatin Remodeling		Nucleotide Excision Repair		Direct Repair		Telomere Repair	
Entrez ID	Symbol	Entrez ID	Symbol	Entrez ID	Symbol	Entrez ID	Symbol	Entrez ID	Symbol	Entrez ID	Symbol	Entrez ID	Symbol	Entrez ID	Symbol	Entrez ID	Symbol	Entrez ID	Symbol
6233	RPS27A	6233	RPS27A	10215	PSMD14	3978	LIG1	328	APEX1	10215	PSMD14	80	ACTB	6233	RPS27A	4255	MGMT	80119	PIF1
7311	UBA52	7311	UBA52	472	ATM	5424	POLD1	27301	APEX2	472	ATM	86	ACTL8A	7311	UBA52	121642	ALKBH2	23049	SMG1
378708	GENPS	199990	FAAP20	641	BLM	5425	POLD2	3978	LIG1	64421	DLCLRE1C	51412	ACTL8B	9716	AQR	2211620	ALKBH3	23293	SMG6
8416	ATRIP	201973	PRIMPOL	8416	SLX4	10714	POLD3	3968	LIG3	7578	BRCC3	57193	ACTR3B	5478	RNF138	54784	ALKBH5	79991	OBFC1
84464	SLX4	5424	POLD1	672	BRCA1	57804	POLD4	5423	POLB	9577	BRE	79913	ACTR5	54841	BIVM	10973	ASCC3	54386	TERF2IP
199990	FAAP20	5425	POLD2	675	BRCA2	2067	ERC1C	5424	POLD1	580	BARO1	64431	ACTR6	84464	SLX4	51008	ASCC1	5976	UPF1
353497	CORT	10714	POLD3	116392	SFR1	9156	EXO1	5426	POLE	472	BRCA1	8289	ARID1A	675	BRCA1	79088	FTO	7013	TERF1
2067	ERC1C	11201	POL1	128074	SWI5	4436	MSH2	2074	ERCHE1	3981	NHEJ1	22893	ARID2	19628	CCND2	84164	ASCC2	7014	TERF2
64789	EXOS	5427	POL2E	AP5S1	55317	4292	MLH1	10721	POLQ	286257	Ctbfat12	29028	ATA2D	1022	CDK7			5884	RAD17
353497	POLN	5429	POLH	253714	MM52L	27030	MLH3	1763	DNA2	84142	FAM175A	546	ATRX	4331	MNAT1			1017	CDK2
2067	ERC1C	11201	POL1	3745757	MSH6	4436	MSH4	2237	FEN1	3978	NHEJ1	22893	ARID2	19628	CCND2			10728	PTGES3
91442	FAAP2A	51426	POLN	8318	CDC45	4437	MSH3	267004	PGBD3	64858	DLCLRE1B	11176	BAZ2A	9557	CHD1L			1736	DKC1
2175	FANCA	353497	POLN	8317	CDK7	4438	MSH4	2237	FEN1	3978	BRD4	23476	GP51	2873	GP51			5558	PRIM2
2187	FANCB	5980	REV3L	135458	HUS1B	4439	MSH5	3146	HMOB1	3980	LIG3	2186	BPTF	1069	CETN2			5557	PRIM1
2176	FANCC	51514	DTL	11144	MSH6	2956	MSH6	8091	HMO2A	3981	LIG4	25855	HUS1B	135458	HUS1B			23649	POL2
2177	FANCD2	7706	TRIM25	3980	LIG3	5395	PMS2	3159	HMGAI1	5422	POLA1	10036	CHAF1A	2068	ERC2			80351	TNKS2
2178	FANCE	9636	ISO15	353497	POLN	5378	PMS1	10075	HUWE1	27343	POLL	8208	CHAF1B	2071	ERC3				
2188	FANCF	10459	MAD2L2	10721	POLQ	4595	MUTHY	8930	MBD4	27343	POLM	1105	CHD1	2965	GTFC23				
2189	FANGC	55666	NPL0C4	51659	GINS2	5111	PCNA	4350	MPG	10721	POLQ	9557	CHD1L	2967	GTFC23				
55215	FANCI	5111	PCNA	7979	SHFM1	5379	PMS2P1	4595	MUTHY	5591	PRKDC	1106	CHD2	2968	GTFC24				
55120	FANCL	25898	RCHY1	642636	RAD21L1	5380	PMS2P2	79661	NEIL1	7334	UBE2N	1107	CHD3	404672	GTFC25				
57697	FANCM	51455	REV1	7334	UBE2N	5383	PMS3P5	252969	NEIL2	22992	KDM5A	1108	CHD4	9978	RBX1				
27033	ZBTB32	5982	RF02	55218	EXO2	10535	RNASEH2A	55247	NEIL3	8924	HERC2	26038	CHD5	8451	CUL4A				
146956	EME1	5983	RF03	2187	FANCB	6117	HPA1	4913	NTHL1	8290	HIST3H3	84181	CHD6	8450	CUL4B				
22909	FAN1	5984	RF04	84893	FBXO18	6118	HPA2	4968	ODG1	29086	BABAM1	55636	CHD7	1642	DDB1				
80186	MUS81	5985	RF05	2237	FEN1	6119	HPA3	142	PARP1	3014	H2AFX	57680	CHD8	10450	PP1A				
64710	NUCKS1	5981	RF01	147872	CCDC155	6996	TDG	10038	PARP2	8359	HIST1H4A	80205	CHD9	64858	DLCLRE1B				
10635	RAD51AP1	6117	HPA1	348654	GEN1	11277	TREX1	5111	PCNA	8366	HIST1H4B	1487	CTBP1	1643	DBR2				
5892	RAD51D	6118	HPA2	548593	SLX1A	25	ABL1	5428	POLQ	8364	HIST1H4C	10364	CTCF	3978	LIG1				
165918	RNF168	6119	HPA3	113510	HELO	7161	TPT3	55170	PRMT6	8360	HIST1H4D	140590	CTCF	3980	LIG3				
9025	RNF8	7314	UBB	3364	HUS1			6117	HPA1	8367	HIST1H4E	30827	CXXC1	3981	LIG4				
6117	HPA1	7316	UBC	3014	H2AFX			6118	HPA2	8361	HIST1H4F	7913	DEK	5423	POLB				
6118	HPA2	9246	UBE2L6	54617	NBR1			6119	HPA3	8365	HIST1H4H	55928	DNAPI1	5424	POL1B				
6119	HPA3	7318	UBA7	23514	SPDR			9401	RECQL4	8294	HIST1H4I	8193	DPF1	5425	POLD2				
5888	RAD51	7353	UFD1L	9907	AP5Z1			8034	SLC25A16	8368	HIST1H4L	5977	DPF2	10714	POLD3				
9637	DLCLRE1A	9100	USP10	84515	MCMB			23583	SMUG1	2547	XRC6	8110	DPF3	57804	POLD4				
201254	CENPA	124793	USP43	254394	MCMB			51548	SIRT6	7520	XRC5	57634	POL2	5426	POL4				
7314	UBB	7415	VCP	286053	NSMCE2			6996	TDG	4292	MLH1	2074	ERCC8	51426	POLK				
7316	UBC	22890	ZBTB1	4361	MRE11			7374	UNG	22976	PAXIP1	1647	GADD45A	27343	POLL				
9768	UBE2T	9768	KIAA1011	23503	MRE11A			10309	CCND1	7336	UBE2V2	4616	GADD45B	7329	UBR2				
7398	USP1	7335	UBE2V1	4683	NBN			55031	USP47	286053	NSMCE2	10912	GADD45G	7334	UBE2N				
7507	HPA1	7336	UBE2V2	10111	RAD50			7486	WRN	4361	MRE11	3054	HCF1C	2067	ERC1C				
2072	ERC04	27434	POLM	22909	FAN1			7515	XRC1C	4683	NBN	3070	HELLS	2074	ERC06				
7517	XRC03	10721	POLQ	NSMCE1	MUS81			200558	APLF	10111	RAD50	6596	HLTF	267004	PTGES3				
80233	FAAP100	55339	WOR33	64859	OBFC2A			4521	NUDT1	9656	MDC1	10362	HMG20B	1161	ERC08				
548593	SLX1A	388988	UBE2NL	4796	TONSIL			143	PARP4	27339	PRPF19	54556	MG3	2176	FANCC				
675	BRCA2			64710	NUCKS1			25961	NUDT13	10624	KAT5	54617	NOB8	3150	HGMN1				
83990	FANCI			197370	NSMCE1					51588	PIAS4	83444	INO80B	10463	SLC39A8				
79728	PALB2			220064	ORAOV1					51720	UIMC1	125476	INO80C	3364	HUS1				
5889	RAD51C			79728	PALB2					55183	RF1	54891	INO80D	57461	ISY1				
672	BRCA1			142	PARP1					165918	RNF168	28399	INO80E	39122	RAB43				
5910	RAD1			10635	RAD51AP1					9025	RNF8	10524	KAT5	57564	UVSSA				
				6421	SFPQ					6419	SETMAR	222229	LRWD1	4287	ATXN3				
				5890	RAD51B					23137	SMC5	114785	MBD6	64210	MM519				
				5889	RAD51C					9937	MTA1	9112	MTA1	7336	UBE2V2				
				5892	RAD51D					7341	SUMO1	57504	MTA3	22909	FAN1				
				25788	RAD54B					7405	UVRAG	10514	MYBBP1A	79661	NEIL1				
				8438	RAD54L					7468	WHSC1	4641	MYC1C	25269	NEIL2				
				5932	RBBP9					7518	XRC04	4678	NASP	55247	NEIL3				
				5965	RECQL					91419	ATP23	8467	SMARCA5	27339	PRPF19				
				51444	RNF138					7158	TP53BP1	56916	SMARCA2D1	4913	NTHL1				
				6117	HPA1					5965	RECQL	50485	SMARCA11	4968	ODG1				
				6118	HPA2					2072	ERC04	6599	SMARCC1	220064	ORAOV1				
				6119	HPA3					7486	WRN	6601	SMARCC2	142	PARP1				
				5888	RAD51					2139	EYAA2	6602	SMARCCD1	5111	PCNA				
				5893	RAD52					10432	RBM14	6603	SMARCCD2	5430	POLR2A				
				9400	RECQL5					28990	ASTE1	6604	SMARCCD3	5431	POLR2B				
				84296	GINS4					4841	NONO	6605	SMARCE1	5432	POLR2C				
				23137	SMC5					9232	PTTG1	10847	SRCAP	5433	POLR2D				
				79677	SMC6					9126	SMC3	28844	TEFT	5436	POLR2E				
				57599	WDR48							7153	TOP2A	5438	POLR2I				
				2072	ERC04							7155	TOP2B	5439	POLR2J				
				7515	XRC03							7161	TPT3	5886	RAD23A				
				7516	XRC02							6944	VP572	5887	RAD23B				
				7517	XRC03							7528	YY1	5892	RAD51D				
				7528	YY1							11244	ZHX1	5932	RBBP8				
				23503	ZFYVE26							10467	ZNHIT1	5982	RF02				
				125150	ZSWIM7							84083	ZRANB3	5983	RF03				
				146956	EME1							8607	RUVEL1	5984	RF04				
				197342	EME2							10856	RUVEL2	5985	RF05				
				2139	EYAA2							26122	EPCC2	5981	RF01				
				5810	RAD1							23054	NCOA6	5434	POLR2E				
				5884	RAD17							29128	UHRF1	5435	POLR2F				
				5891															

Table E2

Upregulated Genes in Severe COPD

Up-Regulated Genes									
Lung eQTL				OSU		LGRC			
GOLD IV vs. GOLD 0	GOLD IV vs. GOLD I,II	GOLD IV vs. GOLD 0	GOLD IV vs. GOLD I,II	GOLD IV vs. GOLD 0	GOLD IV vs. GOLD I,II	GOLD IV vs. GOLD 0	GOLD IV vs. GOLD I,II	GOLD 4 vs. I,II	
84710	64710	84126	84126	7311	27033	7311	27033	27033	
165916	7398	353497	2067	1325	80233	1325	80233	80233	
7507	7507	55215	27033	27033	5425	27033	5425	5425	
10933	6421	80233	80233	80233	10459	80233	10459	10459	
OBCF2A	7528	2072	5425	5425	9100	5425	9100	9100	
6421	51444	55031	80233	10459	135458	10459	135458	135458	
51444	GADD45B	6601	5425	7415	3980	9100	3980	3980	
7528			10714	7335	389898	641	OBCF2A	3014	
1017			5429	27434	3980	3980	197370	197370	
8359			5566	3980	7334	7334	23049	23049	
571			472	7334	7334	3014	7166	7166	
2140			55317	2237	OBCF2A	25			
1105			84893	84296	197370	2139			
1106			3014	25	27301	27301	7161	7161	
GADD45A			9907	328	27301	27301	27301	27301	
GADD45B			84515	3159	23049	23049	3159	3159	
10912			4361	2547	7156	6996	51548	51548	
6601			OBCF2A	51588	6996	7161	8359	8359	
				9112	7161	27301	8365	8365	
				6421	7157	3159	8294	8294	
				84296	60	51548	7341	7341	
				151987	51412	4521	10432	10432	
				29072	8289	5591	55127	55127	
				25	57680	7341	22853	22853	
				3146	1487	9232	23476	23476	
				3159	30827	571	25855	25855	
				8930	10514	10519	GADD45A	GADD45A	
				27339	4641	11200	GADD45B	GADD45B	
				51588	10847	55127	10912	10912	
				55183	10856	51412	222229	222229	
				79913	2068	22893	10514	10514	
				9112	5430	23476	6604	6604	
				10039	5433	25855	10847	10847	
				113130	5439	54891	10856	10856	
				51412	5886	54891	5433	5433	
				10036	5434	222229	4255	4255	
				1106	56949	10514	121642	121642	
				26038	10445	8607	84164	84164	
				57680	1736	10856	7014	7014	
				8193		2068	1736	1736	
				GADD45A		1642			
				GADD45B		5432			
						5433			
						4678			
						10856			
						2965			
						2968			
						9978			
						57461			
						339122			
						MMS19			
						5432			
						5433			
						5439			
						5887			
						5434			
						5437			
						10973			
						84164			

Table E2 Differentially expressed genes. Entrez IDs for differentially expressed genes in GOLD IV vs. GOLD 0 and GOLD IV vs. GOLD I, II in the Lung eQTL, LGRC, and OSU cohorts. For the 15 genes that were identified as differentially expressed across three cohorts, Entrez IDs have been replaced with gene symbols and color coded for easy identification.

Table E2 (cont) Downregulated Genes in Severe COPD

Down-Regulated Genes									
Lung eQTL			OSU			LGR			
GOLD IV vs. GOLD 0	GOLD IV vs. GOLD 0	GOLD IV vs. GOLD I,II	GOLD IV vs. GOLD 0	GOLD IV vs. GOLD I,II	GOLD IV vs. GOLD 0	GOLD IV vs. GOLD 0	GOLD IV vs. GOLD I,II	GOLD IV vs. GOLD 0	GOLD IV vs. GOLD I,II
FANCC	64789	64789	64789	64789	64710	FANCC	64710	FANCC	64789
FANCL	2188	5888	5888	5888	9025	FANCL	9025	FANCL	22909
	10635	7706	FANCC	2175	9937		9937		10635
	9025	22890		2188	51426		51426		7398
	5888	8318	FANCL	57697	51455		51455		7507
	79728	3364		6117	5984		5984		5889
POLI	5810	220064		22909	REF1		253714		672
	51514	4439		5892	113510	POLI	201973	POLI	201973
	7706	56247		9025	84515		5427		5427
REF1	51455	8034		6117	10111		51514		51426
	22890	64421		9937	5985		5985		5980
	55339	22992		201254	REF1		7318		9636
	10213	2140		7316	79677		124739		5111
	55218	51507		7507	4436		11144		51455
	348654	9557		548593	5423		55218		5984
	254394	114785		79728	267004		348654		5985
	220064	29844		5889	3146		23514	REF1	
	125150	7153		672	NUDT1		254394		7318
	197342	10450		5424	64421		10111		22890
	5884	DDB2		10714	84142		220064		119392
NEIL1	5378	7329	POLI	57804	XRCC4		5893		7579
	8034	MMS19		93973		91419	5893		348654
	143			7706	28990		79677		113510
NUDT1				5980	9665		23503		5984
	64421			51455	23064		9126		23514
BRCC3				5983	8467		29072		84515
	3981			5984	29028		4436		254394
	22992			5985	546		5378		286053
WHSC1			REF1		1105		7508		10111
XRCC4				124739	84181	NEIL1			25788
	2140			7415	55636		55247		5985
	9112			7336	80205		4913		23137
	51507			55339	6596		4968		79677
	1106			253714	114785		10038		23503
	114785			11144	7155		55031		5884
	7153			55218	23054	NUDT1			9126
	6944			254394	54841	BRCC3			4436
	54778			4361	404672		5422		29072
	91603		DDB2	10111			8364		4436
	10450			220064	10463	WHSC1			5378
DDB2				25788	4287		28990		7508
	57654		MMS19	5893			83666		8930
	85015			5893	29935		9665	NEIL1	
OBFC1	93973			79677	6512		5883		4588
				57599			11176		10038
				7515	OBFC1		84181		55031
				7529			10664		143
				23503			6596	NUDT1	
				2139			6601	BRCC3	
				1017			6605		84142
				8243			26122		3981
				9126			23054	WHSC1	
				9156			54841	XRCC4	
				4436			2071		91419
				2956					83666
				5378		MMS19	2073		1653
				4595			5037		157570
				5383			25842		9665
				10535		OBFC1			5885
				11277			5557		23064
				1753					56916
				3148					64431
				10075					196528
			NEIL1						11176
				4913					84181
				4968					7913
				10038					6596
				85170					54555
				8034					6605
				23583					7155
				7374					26122
				55031					6594
				7486					54841
			NUDT1						1022
				64421					404672
			BRCC3						3150
				580					10463
				286257					
				84142					
				5422					
				5591					
				8924					
				8366					
				8364					
				8360					
				8368					
				2547					
				22976					
				9656					
				6419					
				7405					
			WHSC1						
			XRCC4						
				91419					
				7158					
				28990					
				4841					
				83666					
				1653					
				9665					
				9112					
				5885					
				23064					
				56916					
				6647					
				5883					
				60					
				86					
				64431					
				196528					
				29028					
				546					
				22893					
				2186					
				8208					
				9557					
				1108					
				84181					
				80205					
				1487					
				10664					
				55929					
				8110					
				57634					
				6596					
				10362					
				54556					
				114785					
				4641					
				6601					
				6604					
				6605					
				7155					
				11244					
				84083					
				23054					
				6594					
				9716					
				54778					
				54841					
				1022					
				2068					
				404672					
				8451					
			DDB2						
				1161					
				3150					
			MMS19						
				10463					
				5430					
				5436					
				5887					
				5435					
				5440					
				29935					
				6613					
				6917					
				2073					
				25842					
				221120					
				10973					
				79068					
				80119					
			OBFC1						
				54386					
				10728					
				5558					
				5557					
				23649					

Table E3

	GOLD 0	GOLD I, II	GOLD IV
n	20	14	23
Age (years)	62.7±9.8	70.0±10.3	54.2±6.9
Male Gender	11 (55)	10 (71.4)	16 (69.2)
Pack-years	30±23 [4]	50±23	54±7
Smoking Status (n)	[2]	[2]	
Current	1	2	0
Former	15	10	22
Never	2	0	1
Coexisting Malignancy	19 (95)	13 (93)	0 (0)

Table E3 Demographic characteristics of lung tissue samples used for RNAseq. Data are expressed as n (%) or mean ± standard deviation unless otherwise stated [] represents missing samples.

Table E4

	Cluster 1	Cluster 2	Cluster 3	p-value
n	65	32	72	
Age (years)	66.2 ±10.1	65.2± 8.3	64.9±9.8	0.72
Male Gender	38 (58.4)	18 (56.3)	39 (54.2)	0.88
Pack-years	60±35	50±31	54±38	0.28
Smoking Status (n)				0.98
Current	5	2	4	
Former	58	29	65	
Never	2	1	3	
Coexisting Malignancy	48 (73.8)	14 (43.8)	35 (48.6)	0.003

Table E4 Demographic characteristics of patient clusters.
Data are expressed as n (%) or mean ± standard deviation unless otherwise stated.

Table E5

Cluster 3 vs. Control	PATHWAYS	FDR
	Immune response_IL-5 signaling via JAK/STAT	2.58416E-14
	Development_PEDF signaling	1.74796E-08
	Renal tubulointerstitial injury in Lupus Nephritis	1.74796E-08
	Immune response_IL-17 signaling pathways	1.74796E-08
	Immune response_IL-3 signaling via JAK/STAT, p38, JNK and NF-kB	1.74796E-08
	Signal transduction_NF-kB activation pathways	1.74796E-08
	Immune response_IL-10 signaling pathway	2.43031E-08
	Immune response_HSP60 and HSP70/ TLR signaling pathway	4.70008E-08
	Th17 cells in CF	2.98976E-07
	Apoptosis and survival_Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway	8.5043E-07
	Neurogenesis_NGF/ TrkA MAPK-mediated signaling	9.74958E-07
	Cell adhesion_ECM remodeling	1.04107E-06
	Immune response_TLR2 and TLR4 signaling pathways	4.58091E-06
	Development_Regulation of epithelial-to-mesenchymal transition (EMT)	4.91049E-06
	Myeloid-derived suppressor cells and M2 macrophages in cancer	4.91049E-06
	Immune response_HMGB1/RAGE signaling pathway	4.91049E-06
	T follicular helper cell dysfunction in SLE	6.89479E-06
	Apoptosis and survival_APRIL and BAFF signaling	7.88042E-06
	Transcription_Role of VDR in regulation of genes involved in osteoporosis	8.35924E-06
	Rheumatoid arthritis (general schema)	8.35924E-06
	PDE4 regulation of cyto/chemokine expression in inflammatory skin diseases	8.35924E-06
	Immune response_Oncostatin M signaling via JAK-Stat	1.19474E-05
	Role of B cells in SLE	1.60612E-05
	Immune response_Oncostatin M signaling via MAPK	1.93912E-05
	Immune response_IL-6 signaling pathway via JAK/STAT	2.52669E-05
	Glomerular injury in Lupus Nephritis	2.86506E-05
	Development_ERBB-family signaling	3.64516E-05
	Immune response_OX40L/ OX40 signaling pathway	4.92197E-05
	Immune response_B cell antigen receptor (BCR) pathway	5.87773E-05
	Immune response_Role of HMGB1 in dendritic cell maturation and migration	7.06489E-05
	Dysregulation of germinal center response in SLE	7.61744E-05
	Apoptosis and survival_Lymphotoxin-beta receptor signaling	8.41162E-05
	Expression targets of Tissue factor signaling in cancer	8.41162E-05
	Stimulation of TGF-beta signaling in lung cancer	9.00069E-05
	Immune response_IL-18 signaling	9.01493E-05
	Signal transduction_PTMs in BAFF-induced non-canonical NF-kB signaling	9.40188E-05
	Th17 cells in CF (mouse model)	0.000102011
	PDE4 regulation of cyto/chemokine expression in arthritis	0.000102011
	Immune response_Bacterial infections in normal airways	0.000102011
	Role and regulation of Prostaglandin E2 in gastric cancer	0.000102011
	Immune response_MIF-mediated glucocorticoid regulation	0.000111028
	Immune response_TNF-R2 signaling pathways	0.000159031
	Immune response_PGE2 signaling in immune response	0.000159031
	Colorectal cancer (general schema)	0.000250931
	Cell adhesion_Chemokines and adhesion	0.000267804
	Immune response_IL-6-induced acute-phase response in hepatocytes	0.000300058
	Immune response_ICOS signaling pathway in T-helper cell	0.000301549
	PGE2 pathways in cancer	0.000402922
	Apoptosis and survival_Anti-apoptotic TNFs/NF-kB/IAP pathway	0.00050595
	Immune response_Role of PKR in stress-induced antiviral cell response	0.000614013

Table E5 cont.

	PATHWAYS	FDR
Cluster 2 vs. Control	Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling	1.85677E-06
	Cytoskeleton remodeling_Cytoskeleton remodeling	2.62659E-05
	Cell adhesion_Integrin inside-out signaling in T cells	6.659E-05
	Immune response_CCL2 signaling	6.659E-05
	Cell adhesion_Histamine H1 receptor signaling in the interruption of cell barrier integrity	6.91542E-05
	Immune response_Classical complement pathway	0.000141904
	Immune response_Alternative complement pathway	0.000141904
	Cell adhesion_Plasmin signaling	0.000206069
	FGF signaling in pancreatic cancer	0.000303336
	Development_MAG-dependent inhibition of neurite outgrowth	0.000360669
	Immune response_C3a signaling	0.000466874
	Cell adhesion_Chemokines and adhesion	0.000466874
	Renal tubulointerstitial injury in Lupus Nephritis	0.000476109
	Signal transduction_IP3 signaling	0.000476109
	Immune response_CCR3 signaling in eosinophils	0.000476109
	Colorectal cancer (general schema)	0.000549706
	Immune response_Lectin induced complement pathway	0.000549706
	Alternative complement cascade disruption in age-related macular degeneration	0.000747639
	Development_Regulation of cytoskeleton proteins in oligodendrocyte differentiation and myelination	0.000968822
	Cytoskeleton remodeling_Regulation of actin cytoskeleton by Rho GTPases	0.001015361
	Cell adhesion_ECM remodeling	0.001015361
	Dysregulation of germinal center response in SLE	0.001085358
	Muscle contraction_GPCRs in the regulation of smooth muscle tone	0.001085358
	Complement pathway disruption in thrombotic microangiopathy	0.001605382
	Cytoskeleton remodeling_Substance P mediated membrane blebbing	0.001637494
	Airway smooth muscle contraction in asthma	0.001652474
	Impaired inhibitory action of lipoxins on neutrophil migration in CF	0.001652474
	B cell signaling in hematological malignancies	0.001652474
	Immune response_T cell subsets: secreted signals	0.001726088
	Development_Regulation of epithelial-to-mesenchymal transition (EMT)	0.002397985
	Cell adhesion_Endothelial cell contacts by junctional mechanisms	0.002397985
	Apoptosis and survival_NGF/ TrkA PI3K-mediated signaling	0.002637393
	Chemotaxis_Inhibitory action of lipoxins on IL-8- and Leukotriene B4-induced neutrophil migration	0.002637393
	Muscle contraction_Regulation of eNOS activity in endothelial cells	0.002642032
	Immune response_B cell antigen receptor (BCR) pathway	0.002642032
	Cell adhesion_Tight junctions	0.002649148
	G-protein signaling_H-RAS regulation pathway	0.002649148
	Muscle contraction_Relaxin signaling pathway	0.002649148
	Neurophysiological process_ACM regulation of nerve impulse	0.002649148
	Cell cycle_Role of Nek in cell cycle regulation	0.00271413
	Cell adhesion_Gap junctions	0.007040667
	Resolution of inflammation in healing myocardial infarction	0.007040667
	Development_Regulation of lung epithelial progenitor cell differentiation	0.007040667
	Oxidative stress_Activation of NADPH oxidase	0.007231906
	ENaC regulation in normal and CF airways	0.007231906
	Glomerular injury in Lupus Nephritis	0.007746357
	Cytoskeleton remodeling_Reverse signaling by Ephrin-B	0.008199773
	Chemotaxis_CCR1 signaling	0.008199773
	Stimulation of TGF-beta signaling in lung cancer	0.008199773
	Development_Role of G-CSF in hematopoietic stem cell mobilization	0.008331283

Table E5 cont.

	PATHWAYS	FDR
Cluster 1 vs. Control	Immune response_IL-5 signaling via JAK/STAT	2.46432E-08
	Neurogenesis_NGF/ TrkA MAPK-mediated signaling	1.80016E-05
	Immune response_IL-6 signaling pathway via JAK/STAT	2.26837E-05
	Immune response_IL-3 signaling via JAK/STAT, p38, JNK and NF-kB	2.26837E-05
	Immune response_IL-18 signaling	3.16719E-05
	Development_Transcription regulation of granulocyte development	3.93554E-05
	Immune response_IL-1 signaling pathway	8.65083E-05
	Reproduction_Gonadotropin-releasing hormone (GnRH) signaling	9.73401E-05
	Immune response_IL-17 signaling pathways	0.000206079
	K-RAS signaling in pancreatic cancer	0.000230174
	Immune response_CD40 signaling	0.000311612
	Immune response_TLR2 and TLR4 signaling pathways	0.000427075
	Development_GM-CSF signaling	0.000427075
	Immune response_HSP60 and HSP70/ TLR signaling pathway	0.00066774
	Immune response_Oncostatin M signaling via MAPK	0.000681542
	Immune response_MIF-mediated glucocorticoid regulation	0.000733887
	Immune response_TLR5, TLR7, TLR8 and TLR9 signaling pathways	0.000777029
	Development_ERBB-family signaling	0.000777029
	Immune response_IL-33 signaling pathway	0.000793299
	Immune response_IL-10 signaling pathway	0.00117069
	Immune response_Substance P-stimulated expression of proinflammatory cytokines via MAPKs	0.00118276
	Renal tubulointerstitial injury in Lupus Nephritis	0.001449424
	Glomerular injury in Lupus Nephritis	0.001933506
	Stimulation of TGF-beta signaling in lung cancer	0.001954887
	Development_PEDF signaling	0.00211156
	Development_EGFR signaling pathway	0.002168513
	Immune response_CCL2 signaling	0.003388931
	Immune response_Platelet activating factor/ PTAFR pathway signaling	0.003496915
	PGE2 pathways in cancer	0.003496915
	Immune response_IL-9 signaling pathway	0.003617684
	Development_YAP/TAZ-mediated co-regulation of transcription	0.003617684
	Transcription_Role of AP-1 in regulation of cellular metabolism	0.00454154
	IGF family signaling in colorectal cancer	0.004981025
	Immune response_Oncostatin M signaling via JAK-Stat	0.005028124
	Myeloid-derived suppressor cells and M2 macrophages in cancer	0.006685753
	Immune response_IL-27 signaling pathway	0.006698825
	T follicular helper cell dysfunction in SLE	0.006698825
	Muscle contraction_Regulation of eNOS activity in endothelial cells	0.006698825
	Development_Leptin signaling via JAK/STAT and MAPK cascades	0.007129372
	Transcription_Transcription regulation of aminoacid metabolism	0.007129372
	Development_Cross-talk between VEGF and Angiopoietin 1 signaling pathways	0.008122061
	Immune response_MIF-induced cell adhesion, migration and angiogenesis	0.008557024
	Development_TGF-beta-dependent induction of EMT via MAPK	0.009237917
	Immune response_Histamine H1 receptor signaling in immune response	0.009953739
	Immune response_CD137 signaling in immune cell	0.011248497
	Development_TGF-beta receptor signaling	0.011248497
	Immune response_C5a signaling	0.011248497
	Development_G-CSF-induced myeloid differentiation	0.011964976
	Immune response_IL-5 signaling via PI3K, MAPK and NF-kB	0.011964976
	Signal transduction_Additional pathways of NF-kB activation (in the cytoplasm)	0.012653182

Table E5 Global gene expression pathways. Analysis of global gene expression pathways associated with Clusters 1, 2, and 3 compared to control patients. The top 50 enriched pathways are listed for each comparison.

Table E6

(A)

	BER		CR		DR		FA		HR		MMR		NER		NHEJ		TR		TLS	
	FDR	NES	FDR	NES	FDR	NES	FDR	NES	FDR	NES	FDR	NES	FDR	NES	FDR	NES	FDR	NES	FDR	NES
FEV1 Percent Predicted	0.14	1.28	0.31	1.09	0.18	-1.2	0.076	1.51	0.13	1.37	0.15	1.26	0.003	1.95	0.12	1.33	0.14	1.33	0.005	1.84
DLCO Percent Predicted	0.57	0.25	0.15	1.31	0.02	-1.61	0.042	1.62	0.18	1.26	0.2	1.22	0.048	1.57	0.55	0.23	0.15	-1.4	0.02	1.73
BODE	0.28	-1.11	0.23	-1.17	0.11	1.27	0.08	-1.43	0.06	-1.5	0.08	-1.4	0.006	-1.86	0.08	-1.38	0.045	-1.56	0.011	-1.88
SF-12 Score	0.37	1.13	0.64	0.65	0.38	-1.04	0.021	1.66	0.1	1.41	0.23	1.25	0.021	1.66	0.48	1.01	0.35	1.11	0.0045	1.92
SGRQ Score	0.67	-0.88	0.21	-1.23	0.22	1.16	0.058	-1.61	0.23	-1.24	0.5	-1	0.058	-1.61	0.39	-1.08	0.15	-1.34	0.092	-1.64
6MWD (meters)	0.16	1.26	0.25	1.13	0.17	-1.21	0.08	1.58	0.04	1.36	0.25	1.15	0.06	1.56	0.14	1.33	0.14	1.29	0.03	1.78
Percent Emphysema	0.13	-1.33	0.38	-1.04	0.04	1.44	0.017	-1.77	0.12	-1.34	0.36	-1.08	0.03	-1.67	0.13	-1.36	0.12	-1.39	0.019	-1.85
Correlation with Features of Decreased COPD severity (FDR)																				
<0.01																				
≥0.01 & <0.05																				
≥0.05 & <0.1																				
Not Significant																				
≥0.05 & <0.1																				
≥0.01 & <0.05																				
Correlation with Features of Increased COPD severity (FDR)																				

(B)

	BER		CR		DR		FA		HR		MMR		NER		NHEJ		TR		TLS	
	p-value	ρ	p-value	ρ	p-value	ρ	p-value	ρ	p-value	ρ	p-value	ρ	p-value	ρ	p-value	ρ	p-value	ρ	p-value	ρ
FEV1 Percent Predicted	0.402	0.14	0.888	0.02	0.151	-0.13	0.020	0.20	0.056	0.17	0.044	0.18	<0.001	0.37	0.015	0.21	0.578	0.06	<0.001	0.33
DLCO Percent Predicted	0.523	0.08	0.543	0.12	0.017	-0.23	0.020	0.22	0.079	0.15	0.036	0.20	<0.001	0.38	0.135	0.13	0.204	0.13	<0.001	0.42
BODE	0.484	-0.11	0.888	-0.04	0.152	0.12	0.020	-0.20	0.052	-0.21	0.036	-0.20	<0.001	-0.38	0.015	-0.23	0.117	-0.16	<0.001	-0.37
SF-12 Score	0.580	0.06	0.888	-0.04	0.221	-0.10	0.013	0.23	0.052	0.18	0.053	0.17	<0.001	0.32	0.104	0.13	0.094	0.18	<0.001	0.32
SGRQ Score	0.826	0.02	0.888	0.01	0.006	0.26	0.020	-0.19	0.056	-0.16	0.122	-0.12	<0.001	-0.32	0.046	-0.17	0.094	-0.19	<0.001	-0.31
6MWD(meters)	0.523	0.08	0.888	-0.02	0.120	-0.16	0.020	0.20	0.056	0.17	0.111	0.14	0.002	0.25	0.015	0.22	0.117	0.16	0.001	0.28
Percent Emphysema	0.343	-0.16	0.543	-0.09	0.017	0.21	0.002	-0.28	0.052	-0.18	0.036	-0.20	<0.001	-0.37	0.015	-0.21	0.312	-0.10	<0.001	-0.37
Correlation with Features of Decreased COPD severity (ρ)																				
≥0.30																				
≥0.20 & <0.30																				
<0.20																				
Not Significant																				
<0.20																				
≥0.20 & <0.30																				
Correlation with Features of Increased COPD severity (ρ)																				

Table E6 Enrichment analysis. DNA repair pathways associated with markers of COPD severity based on **A)** GSEA (Normalized Enrichment Score (NES) and FDR) and **B)** Z-score (Correlation Coefficient (ρ) and p-value). *Definition of abbreviations:* FEV₁ – Forced expiratory volume in one second, DLCO - diffusing capacity of the lungs for carbon monoxide, SGRQ - St. George's Respiratory Questionnaire, BODE - body mass index, airflow obstruction, dyspnea, and exercise capacity, and SF-12 - Short Form Healthy Survey-12, BER - Base excision repair, CR - Chromatin remodeling, DR - Direct repair, FA - Fanconi anemia, HR - Homologous recombination, MMR - Mismatch repair, NER - Nucleotide excision repair, NHEJ - Non-homologous end joining, TR - telomere repair, TLS - Translesion synthesis pathway. 6-minute walk distance – (6MWD)

Table E7

Yellow	FDR
DNA damage_BER-NER repair	7.42E-03
Transcription_Chromatin modification	1.64E-02
DNA damage_DBS repair	1.88E-02
Salmon	
Development_Regulation of angiogenesis	1.68E-03
Transcription_Chromatin modification	8.39E-02
Light Yellow	
Cell adhesion_Amyloid proteins	5.31E-04
Cell adhesion_Cadherins	9.48E-03
Development_Neurogenesis_Synaptogenesis	3.72E-02
Cell adhesion_Cell junctions	3.87E-02
Signal transduction_WNT signaling	
Green	
Translation_Translation initiation	1.92E-02
Sky Blue	
Cell adhesion_Integrin-mediated cell-matrix adhesion	5.79E-02
Turquoise	
Inflammation_IL-6 signaling	8.32E-05
Cytoskeleton_Intermediate filaments	1.73E-04
Inflammation_Amphoterin signaling	2.35E-04
Apoptosis_Apoptotic nucleus	2.35E-04
Inflammation_Protein C signaling	4.86E-04
Cell cycle_G1-S Interleukin regulation	6.16E-04
Inflammation_Histamine signaling	6.16E-04
Development_Ossification and bone remodeling	6.16E-04
Apoptosis_Death Domain receptors & caspases in apoptosis	6.68E-04
Immune response_TCR signaling	1.13E-03
Immune response_Th17-derived cytokines	1.93E-03
Cell adhesion_Platelet-endothelium-leucocyte interactions	2.37E-03
Inflammation_IgE signaling	2.37E-03
Inflammation_Neutrophil activation	2.37E-03
Inflammation_MIF signaling	2.87E-03
Inflammation_IL-2 signaling	2.87E-03
Inflammation_IL-10 anti-inflammatory response	2.87E-03
Cardiac development_Role of NADPH oxidase and ROS	3.43E-03
Inflammation_TREM1 signaling	3.79E-03
Inflammation_Inflammasome	4.10E-03
Immune response_Innate immune response to RNA viral infection	4.93E-03
Reproduction_Feeding and Neurohormone signaling	5.13E-03
Inflammation_Innate inflammatory response	5.14E-03
Cell cycle_G1-S Growth factor regulation	7.22E-03
Immune response_BCR pathway	8.43E-03
Chemotaxis	9.71E-03
Apoptosis_Apoptotic mitochondria	1.46E-02
Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT	1.95E-02
Cell cycle_G1-S	2.63E-02
Inflammation_NK cell cytotoxicity	2.73E-02
Inflammation_IL-4 signaling	3.22E-02
Inflammation_IL-12,15,18 signaling	3.66E-02

Table E7 Pathway enrichment for weighted gene co-expression network modules (WGCNA). The enriched processes associated with the WGCNA modules most closely associated with clinical indices of COPD severity (FDR <0.05).

Table E8




Figure E8 Gene significance (GS) versus module membership (MM) for the Yellow module. Weighted gene co-expression network analysis (WGCNA) derived MM were plotted against GS for the following traits: **A)** FEV₁ percent predicted **B)** percent emphysema **C)** DLCO percent predicted, and **D)** BODE index. All DDRT genes (**Supplemental Table 1**) within the module are identified.